Vanda Pharmaceuticals' board is unimpressed with takeover offers from both Cycle Pharma and Future Pak, saying they both “substantially undervalue” the company.
In a US Presidential debate that was low on policy substance and high on hyperbole, falsehoods, and personal attacks, pharma industry issues played a minor role, but did crop up in ways bot